The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: A systematic review

BMC Medicine

Volumn 16, Issue 1, 2018, Pages

  Haeusler, Ilsa L ^a,b   Chan, Xin Hui S ^b,c,d   Guérin, Philippe J ^a,b   White, Nicholas J ^b,c,d  

^a WorldWide Antimalarial Resistance Network   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antimalarials; Arrhythmia; Electrocardiogram; Malaria; Mass drug administration; Piperaquine; QT; Quinolines; Systematic review; Torsade de pointes

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; HALOFANTRINE; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUINIDINE; QUININE; QUINOLINE; QUINOLINE DERIVATIVE;

ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL EVALUATION; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; ELECTROCARDIOGRAPHY; FAINTNESS; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; MALARIA FALCIPARUM; MATHEMATICAL ANALYSIS; MONOTHERAPY; PLASMODIUM VIVAX MALARIA; POOLED ANALYSIS; QT INTERVAL; QT PROLONGATION; SEX DIFFERENCE; SYSTEMATIC REVIEW; ADULT; FEMALE; MALE; PATHOLOGY; YOUNG ADULT;

ADULT; ANTIMALARIALS; CARDIOTOXICITY; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; QUINOLINES; YOUNG ADULT;

EID: 85056123728     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-018-1188-2     Document Type: Article

References (53)

1. White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7:549-58.
2. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 1993;341:1054-6.
3. World Health Organization. Guidelines for the treatment of malaria. Third edition. 2015. http://apps.who.int/iris/bitstream/handle/10665/162441/9789241549127-eng.pdf;jsessionid=FF86896C56304582909FE8E5C71BB30A?sequence=1. Accessed 18 Oct 2018.
4. European Medicines Agency. Eurartesim - summary of product characteristics. 2011. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/001199/WC500118113.pdf. Accessed 18 Oct 2018.
5. Gutman J, Kovacs S, Dorsey G, Stergachis A, Ter Kuile FO. Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2016;17:2095-128.
6. Yap Y, Camm J. Drug induced QT prolongation and Torsades de Pointes. Heart. 2003;89:1363-72.
7. Bouchaud O, Imbert P, Touze JE, Dodoo ANO, Danis M, Legros F. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J. 2009;8:289.
8. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049-58.
9. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One. 2011;6:e14501.
10. Na-Bangchang K, Limpaibul L, Thanavibul A, Tan-Ariya P, Karbwang J. The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol. 1994;38:278-81.
11. Khan SJ, Munib S. Efficacy of halofantrine hydrochloride in vivax malaria. J Postgrad Med Inst. 2005;19:276-80.
12. Win K, Than M, Thwe Y. Comparison of combinations of parenteral artemisinin derivatives plus oral mefloquine with intravenous quinine plus oral tetracycline for treating cerebral malaria. Bull World Health Organ. 1992;70:777-82.
13. Harinasuta T, Bunnag D, Vanijanond S, Charoenlarp P, Suntharasmai P, Chitamas S, et al. Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose. Bull World Health Organ. 1987;65:363-7.
14. Karbwang J, Bangchang KN, Bunnag D, Harinasuta T. Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria. Bull World Health Organ. 1991;69:207-12.
15. Bunnag D, Karbwang J, Viravan C, Chitamas S, Harinasuta T. Clinical trials of mefloquine with tetracycline. Southeast Asian J. trop. Med. Public Health 1992;23:377-382.
16. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SSS, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010;375:1457-67.
17. Karbwang J, Na Bangchang K, Bunnag D, Harinasuta T, Laothavorn P. Cardiac effect of halofantrine. Lancet. 1993;342:501.
18. Adjei GO, Oduro-Boatey C, Rodrigues OP, Hoegberg LC, Alifrangis M, Kurtzhals JA, et al. Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine. Malar J. 2012;11:420.
19. Ngouesse B, Basco LK, Ringwald P, Keundjian A, Blackett KN. Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg. 2001;65:711-6.
20. Lavallée I, Marc E, Moulin F, Treluyer JM, Imbert P, Gendrel D. Cardiac rhythm disturbances and prolongation of the QTc interval with halofantrine. Arch Pédiatrie. 2001;8:795-800.
21. Sowunmi A, Falade CO, Oduola AM, Ogundahunsi OA, Fehintola FA, Gbotosho GO, et al. Cardiac effects of halofantrine in children suffering from acute uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 1998;92:446-8.
22. Miller RS, Wongsrichanalai C, Buathong N, McDaniel P, Walsh DS, Knirsch C, et al. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am J Trop Med Hyg. 2006;74:401-6.
23. Sabchareon A, Chongsuphajaisiddhi T, Sinhasivanon V, Chanthavanich P, Attanath P. In vivo and in vitro responses to quinine and quinidine of Plasmodium falciparum. Bull World Health Organ. 1988;66:347-52.
24. Liu Y, Hu C, Liu G, Jia J, Yu C, Zhu J, et al. A replicate designed bioequivalence study to compare two fixed-dose combination products of artesunate and amodiaquine in healthy Chinese volunteers. Antimicrob Agents Chemother. 2014;58:6009-15.
25. Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, Socheat D, et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol. 2003;57:93-9.
26. Bethell DB, Phuong PT, Phuong CX, Nosten F, Waller D, Davis TM, et al. Electrocardiographic monitoring in severe falciparum malaria. Trans R Soc Trop Med Hyg. 1996;90:266-9.
27. Gargano N, Ubben D, Tommasini S, Bacchieri A, Corsi M, Bhattacharyya PC, et al. Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malar J. 2012;11:233.
28. Jittamala P, Pukrittayakamee S, Ashley E, Nosten F, Hanboonkunupakarn B, Lee S, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2015;59:505-13.
29. van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg. 1999;61:964-7.
30. Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, et al. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother. 2014;58:6056-67.
31. Roggelin L, Pelletier D, Hill JN, Feldt T, Hoffmann S, Ansong D, et al. Disease-associated QT-shortage versus quinine associated QT-prolongation: Age dependent ECG-effects in Ghanaian children with severe malaria. Malar J. 2014;13:219.
32. Baiden R, Oduro A, Halidou T, Gyapong M, Sie A, Macete E, et al. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malar J. 2015;14:160.
33. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One. 2009;4(11):e7871.
34. Valecha N, Phyo AP, Mayxay M, Newton PM, Krudsood S, Keomany S, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One. 2010;5(7):e11880.
35. Mayxay M, Keomany S, Khanthavong M, Souvannasing P, Stepniewska K, Khomthilath T, et al. A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate- mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. Am J Trop Med Hyg. 2010;83:1221-9.
36. Darpo B, Ferber G, Siegl P, Laurijssens B, Macintyre F, Toovey S, et al. Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria. Br J Clin Pharmacol. 2015;80:706-15.
37. Krudsood S, Looareesuwan S, Wilairatama P, Leowattana W, Tangpukdee N, Chalermrut K, et al. Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand. Trop Med Int Heal. 2011;16:458-65.
38. Mytton OT, Ashley EA, Peto L, Price RN, La Y, Hae R, et al. Short report: electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg. 2007;77:447-50.
39. Ogutu B, Juma E, Obonyo C, Jullien V, Carn G, Vaillant M, et al. Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine. Malar J. 2014;13:498.
40. Wernicke JF, Faries D, Breitung R, Girod D. QT correction methods in children and adolescents. J Cardiovasc Electrophysiol. 2005;16:76-81.
41. Price RN, Nosten F, White NJ. Letters to the editor. Am J Trop Med Hyg. 1998;59:504.
42. World Health Organisation. Definitions by WHO. 2003. http://www.who.int/medicines/areas/quality-safety/safety-efficacy/trainingcourses/definitions.pdf. Accessed 18 Oct 2018.
43. Evidence synthesis and meta-analysis: report of CIOMS Working Group X. Council for International Organizations of Medical (CIOMS). 2016.
44. WHO Evidence Review Group. The cardiotoxicity of antimalarials. 2017. http://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf. Accessed 18 Oct 2018.
45. Chan XHS, Win YN, Mawer LJ, Tan JY, Brugada J, White NJ. Risk of sudden unexplained death after use of dihydroartemisinin - piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis World Health Organization. 2018;3099:1-11.
46. Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet. 2018;391:1378-90.
47. Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, H. T, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012;366:1298-1309.
48. Morris CA, Lopez-Lazaro L, Jung D, Methaneethorn J, Duparc S, Borghini-Fuhrer I, et al. Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers. Am J Trop Med Hyg United States. 2012;86:489-95.
49. Kayentao K, Doumbnao OM, Kimani J, Tshefu AK, Kokolomami JHT, Ramharter M, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomigobara K Pénali, Louis K Offianan, André T Bhatt, Kirazed controlled trial. Malar J. 2012;11:364.
50. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Hear. Rhythm. 2005;2:569-74.
51. Isbister GK. How do we assess whether the QT interval is abnormal: myths, formulae and fixed opinion. Clin Toxicol. 2015;53:189-91.
52. Malik M, Färbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002;87:220-8.
53. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Topic E 14 The Clinical Evaluation of QT / QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (CHMP/ICH/2/04). 2005. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002879.pdf. Accessed 18 Oct 2018.